IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone

  • STATUS
    Recruiting
  • End date
    Jun 21, 2023
  • participants needed
    44
  • sponsor
    NorthShore University HealthSystem
Updated on 21 April 2022
urinary tract infection
irritable bowel syndrome
discomfort
naltrexone
lower urinary tract symptoms
nocturia
cystoscopy
bladder pain
urinary urgency
pain disorders
Accepts healthy volunteers

Summary

Interstitial cystitis/painful bladder syndrome (IC/PBS) is a debilitating condition with symptoms of urinary urgency, frequency, nocturia (waking up at night to void), and pain, without evidence of urinary tract infection or other identifiable causes. IC/PBS often coexists with other chronic pain syndromes, such as irritable bowel syndrome, chronic fatigue syndrome, and fibromyalgia.

Several treatments exist for IC/PBS; some are not effective, others are time consuming for patients to receive, some can take weeks to months before they become effective, and many have risks associated with them. Low-dose naltrexone (LDN) has demonstrated improvement of symptoms in conditions associated with IC/PBS. LDN is defined as less than 5mg of naltrexone. Some adverse effects have been reported with LDN, the most common are vivid dreams, nightmares, and insomnia.

The investigators hypothesis LDN will have greater than 30% reduction in symptoms as defined by the Interstitial Cystitis Symptom Index in patients diagnosed with IC/PBS from baseline when compared to placebo. The 30% reduction in pain is a standard outcome measure in the pain literature. This improvement has been seen in prior studies where LDN was used to treat pain syndromes.

This will be a randomized double-blinded placebo-controlled prospective trial. Patients meeting diagnostic criteria for IC/PBS by American Urologic Association (AUA) guidelines will be eligible, and then must then meet all applicable inclusion and exclusion criteria. Study participants will sign a consent, complete several questionnaires, give a blood sample to measure liver function tests, and once at home, complete a 24-hour bladder diary.

Participants will be randomized to receive either placebo or study medication. Participants will be instructed to take one capsule nightly for two weeks, then increase to two capsules nightly for four weeks. They will be given a log to record the date and time they take the medication. All study participants will also receive first-line behavioral therapy for IC/PBS of a bladder diet and bladder drills.

After six weeks, participants will complete a second bladder diary. They will then complete the exit study questionnaires, have a second liver function test, return any unused medication, and meet with their doctor to discuss conventional treatment options for IC/PBS.

Details
Condition Interstitial Cystitis, Painful Bladder Syndrome, Bladder Pain Syndrome, Low Dose Naltrexone, Low-dose Naltrexone, Naltrexone
Treatment Placebo Oral Tablet, Low-dose naltrexone
Clinical Study IdentifierNCT04313972
SponsorNorthShore University HealthSystem
Last Modified on21 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients aged eighteen and older
Meet criteria for IC/PBS as defined by the American Urology Association as "an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms or more than six weeks duration, in the absence of infection or other identifiable causes" (8)
Newly diagnosed and treatment naïve for IC/PBS or previously diagnosed with IC/PBS, but who have no received treatment in the past four weeks. Patient who use anti-inflammatory medication on an as needed basis in the four weeks prior to the study will be included
Have had a cystoscopy in the last 6 months prior to study entry to rule out confounding conditions
English speaking
Working telephone number
Able to provide a blood sample to evaluate liver enzymes
Able to attend research visits

Exclusion Criteria

Patients under the age of 18
Patients with known liver disease, including total bilirubin >1.2, AST> 32, ALT> 54
Patients with known kidney disease
Patients who have thyroid disease and who are taking thyroid replacement medications
Patients with known neurologic disease affecting bladder function
Patients with known bladder or urethral cancer
Patients with bladder, urethral, or ureteral calculi
Patients who have had a positive urine culture or a clinical UTI in the past 6 weeks
Patients who are currently pregnant or breast feeding (15)
Patients who are actively using opioid analgesics
Patients with moderate-severe alcohol use disorder
Patients who are actively using sleep aids
Patients who are regularly using anti-inflammatory medications, such as daily Celebrex for arthritis. Those who use an anti-inflammatory medication on an as needed basis may use the medication prior to enrollment in the study
Patients who have had a known adverse reaction to naltrexone
Patients who are acutely ill
Patients who are diagnosed with a significant psychological comorbidity that would interfere with study participation (32)
Patients who have had a bladder instillation or had oral medical treatment for IC/PBS in the past four weeks
Patients diagnosed with other chronic pelvic pain syndromes, such as endometriosis
Patients who are unable to swallow pills/capsules
Patients who have had previous treatment with low-dose naltrexone
Patients who have previously scheduled surgeries or procedure during the study time period that would require analgesia
Patients who are sexually active and of childbearing potential who are unwilling to use an established and reliable form of contraception for the duration of the study
Patients who are unwilling to have a serum blood test to assess serum transaminases and serum bilirubin
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note